COR Price Prediction Next Week
Based on the provided data and current market context, here's the analysis for COR's price prediction for next week:
Technical Analysis
The technical indicators show:
- RSI(14) at 71.70 indicates an overbought condition
- MACD at 3.48 shows positive momentum
- Price is trading above both 20-day SMA (235.34) and 60-day SMA (238.21)
- Fibonacci levels indicate key resistance at 251.27 and support at 235.69
News Sentiment & Fundamental Factors
- Recent Q4 earnings beat expectations with adjusted EPS of $3.34
- Baird raised price target to $292 (Street-high) citing strong MSO deal potential
- Wall Street consensus shows "Moderate Buy" rating with mean price target of $271.43
- Company's specialty products segment, particularly GLP-1 drugs, showing strong growth momentum
- Fiscal 2025 guidance projects 7-9% revenue growth
Price Prediction for Next Week Based on technical and fundamental analysis:
Target Prices:
- Resistance: $251.27 (Fibonacci R2)
- Support: $235.69 (Fibonacci S1)
Expected Movement: The stock is likely to experience a short-term pullback early in the week due to overbought RSI conditions, finding support around $235-236 level. However, strong fundamental backdrop and positive MACD suggest the dip could be bought, potentially pushing the price toward $251 resistance level by week's end.
Trading Recommendation SELL at current levels ($247.60) with these parameters:
- Entry: $247.60
- Target: $235.69
- Stop Loss: $251.27
The recommendation is based on overbought technical conditions suggesting a higher probability of near-term pullback, providing a favorable risk-reward setup for a short-term trade.
COR Similar Chart Price Prediction
The price of COR is predicted to go up 0.51%, based on the high correlation periods with TPVG. The similarity of these two price pattern on the periods is 98.17%.
COR
TPVG
Up: 0.51%Similarity: 98.17%
COR Revenue Forecast
COR EPS Forecast
COR FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
COR VS S&P500
Cencora distributes pharmaceutical products to nearly one third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.
A robust demand for GLP-1s (diabetes drug) provides a strong tailwind to Cencora's top line and allows the distributor to offer other high-margin services to both manufacturers and customers.
Technology advancements continue to improve Cencora's performance and present new opportunities for wholesalers.
COR Analyst's Forecast
Eric Luebchow
Wells Fargo
Hold
Price Target
$249 → $237
Upside
+2.05%
Wells Fargo lowered the firm's price target on Cencora to $237 from $249 and keeps an Equal Weight rating on the shares. The firm updated estimates and price targets for the drug distribution group following the results and recent mergers. It is "generally constructive" on core distribution fundamentals into 2025, but says valuations and overhangs leave it neutral across the group.
Kevin Caliendo
UBS
Strong Buy
Price Target
$275 → $285
Upside
+15%
John Belton
Evercore ISI Group
Buy
Price Target
$270 → $250
Upside
+13.21%